DE60335647D1 - Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden - Google Patents

Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden

Info

Publication number
DE60335647D1
DE60335647D1 DE60335647T DE60335647T DE60335647D1 DE 60335647 D1 DE60335647 D1 DE 60335647D1 DE 60335647 T DE60335647 T DE 60335647T DE 60335647 T DE60335647 T DE 60335647T DE 60335647 D1 DE60335647 D1 DE 60335647D1
Authority
DE
Germany
Prior art keywords
treatment
ischemia
betablocker
pyrroloquinoline quinone
reperfusion damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335647T
Other languages
English (en)
Inventor
Paul J Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CLF Medical Technology Acceleration Program Inc
Original Assignee
CLF Medical Technology Acceleration Program Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CLF Medical Technology Acceleration Program Inc filed Critical CLF Medical Technology Acceleration Program Inc
Application granted granted Critical
Publication of DE60335647D1 publication Critical patent/DE60335647D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60335647T 2002-05-15 2003-05-14 Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden Expired - Lifetime DE60335647D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/146,566 US7276514B2 (en) 2002-05-15 2002-05-15 Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
PCT/US2003/015187 WO2003097056A1 (en) 2002-05-15 2003-05-14 Pyrroloquinoline quinone for treatment of cardiac injury and methods of use thereof

Publications (1)

Publication Number Publication Date
DE60335647D1 true DE60335647D1 (de) 2011-02-17

Family

ID=29418840

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60335647T Expired - Lifetime DE60335647D1 (de) 2002-05-15 2003-05-14 Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden

Country Status (8)

Country Link
US (2) US7276514B2 (de)
EP (1) EP1558256B1 (de)
JP (1) JP2005530786A (de)
AT (1) ATE493985T1 (de)
AU (1) AU2003237851A1 (de)
CA (1) CA2497601A1 (de)
DE (1) DE60335647D1 (de)
WO (1) WO2003097056A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US7276514B2 (en) 2002-05-15 2007-10-02 Charitable Leadership Foundation - Medical Technology Acceleration Program Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
WO2005107871A2 (en) * 2004-05-05 2005-11-17 Clf Medical Technology Acceleration Program, Inc. Pyrroloquinoline quinone drugs for treatment of cardiac injury
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US9139630B2 (en) 2006-07-11 2015-09-22 Rutgers, The State University Of New Jersey Compositions and methods for preparing recombinant MG53 and methods for optimizing same
US9458465B2 (en) * 2007-12-04 2016-10-04 Rutgers, The State University Of New Jersey Compositions and methods to modulate cell membrane resealing
JP5228912B2 (ja) * 2006-09-08 2013-07-03 三菱瓦斯化学株式会社 高血圧改善剤
JP5672751B2 (ja) * 2010-04-07 2015-02-18 三菱瓦斯化学株式会社 ピロロキノリンキノンを含むリポソーム
US20130123340A1 (en) * 2010-05-11 2013-05-16 Peking University, Office Of Technology Transfer Compositions and methods for the treatment and prevention of cardiac ischemic injury
KR101496794B1 (ko) 2010-11-05 2015-02-27 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 조직 손상에 대한 진단 마커로서의 혈청 ｍｇ５３
WO2012157721A1 (ja) * 2011-05-17 2012-11-22 三菱瓦斯化学株式会社 ピロロキノリンキノンと糖を含むリポソーム
NO2722331T3 (de) 2011-06-16 2018-02-03
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2017050171A1 (zh) * 2015-09-25 2017-03-30 浙江海正药业股份有限公司 吡咯并喹啉醌钠盐的晶型及其制备方法和用途
US20190298684A1 (en) * 2018-03-27 2019-10-03 So Young Life Sciences Corporation Compositions For Reducing Negative Effects Of Alcohol Consumption
CN110870866A (zh) * 2018-09-03 2020-03-10 浙江医药股份有限公司新昌制药厂 吡咯喹啉醌在制备用于防治急性高原反应和急性高原低氧损伤的药物中的应用
IT202000025603A1 (it) * 2020-10-28 2022-04-28 Longeva Health S R L Composizione per prevenire e trattare lo scompenso e/o l’insufficienza cardiaca

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1302275C (en) * 1986-08-07 1992-06-02 Yuji Narutomi Enzyme inhibitor
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
US5145862A (en) * 1990-08-16 1992-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
US5091391A (en) * 1990-08-16 1992-02-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
JP3218038B2 (ja) * 1991-09-09 2001-10-15 ワーナー−ランバート・コンパニー 尿酸***促進剤およびｅａａ拮抗剤の組合せのための医薬組成物
AU3222893A (en) 1991-11-25 1993-06-28 University Of Michigan, The Therapeutic composition and method for preventing reperfusion injury
US5460819A (en) 1991-12-13 1995-10-24 Children's Medical Center Corporation Method for treating PQQ-responsive heavy metal toxicity
US5616576A (en) * 1994-07-12 1997-04-01 The Children's Medical Center Corporation Controlling bone resorption with pyrroloquinoline quinone (PQQ) and related compounds
JP4777489B2 (ja) 1997-03-31 2011-09-21 ザ チルドレンズ メディカル センター コーポレーション アポトーシス性酵素を不活性化するためのニトロシル化
WO2004010924A2 (en) * 2002-04-04 2004-02-05 Children's Medical Center Corporation Pyrroloquinoline quinone drugs as a neuroprotectant and methods of use thereof
US7276514B2 (en) * 2002-05-15 2007-10-02 Charitable Leadership Foundation - Medical Technology Acceleration Program Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof

Also Published As

Publication number Publication date
JP2005530786A (ja) 2005-10-13
AU2003237851A1 (en) 2003-12-02
EP1558256B1 (de) 2011-01-05
ATE493985T1 (de) 2011-01-15
US20080221145A1 (en) 2008-09-11
US20030216424A1 (en) 2003-11-20
WO2003097056A1 (en) 2003-11-27
US7276514B2 (en) 2007-10-02
CA2497601A1 (en) 2003-11-27
EP1558256A1 (de) 2005-08-03

Similar Documents

Publication Publication Date Title
DE60335647D1 (de) Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
ATE419859T1 (de) Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
MX2007007781A (es) Composiciones cardiovasculares.
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
ATE296094T1 (de) Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
MX2007005723A (es) Articulos para tratamiento que pueden amoldarse a una forma subyacente.
ATE499098T1 (de) Verwendung von parp-1-hemmern
ATE473728T1 (de) Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
DE602005016198D1 (de) Verwendung von Hülsenfrüchten zur Herstellung von Produkten zum Schutz oder Behandlung von radiotherapie-bedingten Hautschäden
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.
CY1108042T1 (el) Θεραπεια εντερικων καταστασεων με ν-2,3,3-τετραμεθυλδικυκλο[2.2.1]επταν-2-αμινη
WO2007130509A3 (en) Pyrroloquinoline quinones and use thereof
DE602005016729D1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
ATE516040T1 (de) Zusammensetzung und verwendung zur vorbeugung oder behandlung von stomatitis
ATE420089T1 (de) Substituierte azachinazoline mit antiviraler wirkung
CY1107562T1 (el) Χρηση των ν-(2-αρυλ-προπιονυλ)-σουκλφοναμιδιων για τη θepαπεια του τραυματος του νωτιαιου μυελου
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
NO20060420L (no) 2-aminobenzoylderivater
DE60313803D1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
WO2005107871A3 (en) Pyrroloquinoline quinone drugs for treatment of cardiac injury
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии